PaxMedica is a biopharmaceutical company developing anti-purinergic drug therapies for neurological disorders. Its lead product, PAX-101, treats several indications, including autism spectrum disorder, chronic fatigue syndrome, and COVID-19. In addition, the company is developing an intranasal formulation of suramin, PAX-102, for neurologic indications.